We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

In its fourth quarter 2024 investor letter, Parnassus Core Equity Fund emphasized stocks such as Vertex Pharmaceuticals ...

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...

KING OF PRUSSIA, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) today announced that it will host an Investor Day on Wednesday, March 19, in Philadelphia, PA. The event will ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Over the last 7 days, the United States market has dropped 2.7%, but it has shown resilience with an 11% rise over the past year and earnings forecasted to grow by 14% annually. In this context, ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Rouse had presented with symptoms including intense swelling in her legs that she originally thought could be linked to her ...

Is now the time to buy Vertex Pharmaceuticals, or should you be careful about including it in your portfolio? Check out our in-depth research report to see what our analysts have to say, it’s free. We ...

Vertex Pharmaceuticals Inc.’s new non-opioid ... The medication, called Journavx, got US regulatory clearance in January. The financial success of new drugs largely depends on how they’re ...